赛多利斯 Sartorius  百得 Biohit    www.biohit.com www.biohitchina.com
Biohit(芬兰百得)是一家跨国生物科技公司，开发，生产和市场，如移液器和吸头以及诊断测试和分析系统的液体处理产品。

我们的产品用于研究，卫生保健和全球实验室。

●成立于1988年Suovaniemi教授
●业务范围：液体处理和诊断
●总部设在芬兰赫尔辛基。
●附属公司位于法国，德国，英国，俄罗斯，印度，中国， 日本和美国。 在新加坡有一个代表处。
●生产工厂位于芬兰和中国。
●Biohit(芬兰百得)的产品销往约70个国家的450个分销商。

创新和专利
Biohit(芬兰百得)不断地致力于创新和发展。 百得以其新的技术，产品和服务及研究成果用于开发的早期发现和预防疾病的安全和符合成本效益的实验室工作以及诊断测试的液体处理解决方案。

产品包括用于研究机构，医疗保健和工业实验室和手动、电动移液器，吸头并提供使用技巧以及维修和校准服务。

Biohit(芬兰百得)全球集团
本集团成员来自11个国家约370人。 总部设在芬兰赫尔辛基，在法国，德国，英国，俄罗斯，印度，中国，日本和美国的分公司，并在新加坡设有代表处。 此外，Biohit(芬兰百得)的产品销往约70个国家的450个分销商。

2006年芬兰百得实验室仪器（中国）有限公司(BiohitChina)成立，作为在亚太地区唯一一家子公司，百得中国(BiohitChina)将持续发扬不断创新的品牌精神，并承诺将最好的产品和最优质的服务带到中国 ！
2011年赛多利斯(Sartorius)收购芬兰百得(Biohit )移液器业务

  


百得(Biohit)上海分公司
地址：中国上海延安西路65号国际贵都大酒店办公楼501室
电话：+86-21-62485589
传真：+86-21-62487786
邮编：200040
邮箱：info@biohitchina.com

移液器部联系：销售部
电话：+86-21-62485589

诊断试剂部联系人：冯伟翔
电话：+86-21-62485589-15

全国区域负责人
●华东区
地址：中国上海延安西路65号国际贵都大酒店办公楼501室
电话：021-62485589
传真：021-62487786
联系人：台红华

●华北区
地址：北京海淀区复兴路甲38号嘉德公寓1521室
电话：010-88203819
传真：010-88203871
联系人：祖晓艳

●华南区
地址：广州天河区龙口东路342号天诚广场A804室
电话：020-38460632
传真：020-38469632
联系人：周晓敏

●华中区
地址：武汉市武昌区中南路3号阜华领秀中南大厦2603室
电话：027-87332439
传真：027-87332439
联系人：熊馨
●西南区
地址：成都市西大街84号金色夏威夷A座1428室
电话：028-86633678
传真：028-86633678
联系人：刘丹凤
●西北区
地址：西安市碑林区金花北路东窑坊小区1号楼902室
电话：029-83282336
传真：029-83282336
联系人：高振华
Biohit is a globally operating biotechnology company that develops, manufactures and markets liquid handling products such as pipettes and pipette tips as well as diagnostic tests and analysis systems.

Our products are used by research, health care and industrial laboratories world wide.

Established in 1988 by Professor Osmo Suovaniemi
Business areas: Liquid handling and Diagnostics
Headquartered in Finland, Helsinki.
Subsidiaries are located in France, Germany, the UK, Russia, India, China, Japan and the USA. There is a representative office in Singapore.

Production plants are located in Finland and China.
Biohit's products are sold by approximately 450 distributors in 70 countries.
Biohit Oyj's share (BIOBV) is quoted on NASDAQ OMX Helsinki since June1999, Small cap/Healthcare.

Innovations and patents
Biohit’s operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.

Business segments

Liquid handling
Products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories.

Diagnostics
Comprises products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. The Acetium innovation was developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. The key objective of the diagnostics business is to prevent diseases of the gastrointestinal tract.

Biohit Group worldwide
The Biohit Group employs around 370 people in eleven countries. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA, and a representative office in Singapore. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries.

Biohit Oyj on the stock exchange
Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. More information about the share and financials is available in the Investors section of this site.